LETROZOLE TEVA

País: Israel

Idioma: inglés

Fuente: Ministry of Health

Ingredientes activos:

LETROZOLE

Disponible desde:

TEVA ISRAEL LTD

Código ATC:

L02BG04

formulario farmacéutico:

TABLETS

Composición:

LETROZOLE 2.5 MG

Vía de administración:

PER OS

tipo de receta:

Required

Fabricado por:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

Área terapéutica:

LETROZOLE

indicaciones terapéuticas:

Letrozole teva tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: Letrozole teva is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Fecha de autorización:

2014-12-31

Información para el usuario

PATIENT LEAFLET IN ACCORDANCE WITH THE
PHARMACISTS’ REGULATIONS (PREPARATIONS) – 1986
The medicine is dispensed with a doctor's prescription only
LETROZOLE TEVA
TABLETS
COMPOSITION
EACH TABLET CONTAINS:
Letrozole 2.5 mg
For information regarding inactive ingredients and allergens,
see section 2 - “Important information about some ingredients
of the medicine” and section 6 - “Additional information”.
READ THE ENTIRE LEAFLET CAREFULLY BEFORE USING THE MEDICINE.
This leaflet contains concise information about the medicine.
If you have additional questions, refer to the doctor or the
pharmacist.
This medicine has been prescribed for treatment of your
illness. Do not pass it on to others. It may harm them even if it
seems to you that their illness is similar.
1. WHAT IS THE MEDICINE INTENDED FOR?
•
Adjuvant
treatment
for
early-stage
breast
cancer
in
postmenopausal women.
•
Extended adjuvant treatment for early breast cancer in
postmenopausal women following standard adjuvant tamoxifen
therapy.
•
Treatment
of
advanced
or
metastatic
breast
cancer
in
postmenopausal women.
•
Treatment of advanced breast cancer in postmenopausal
women with disease progression after treatment with anti-
estrogens.
THERAPEUTIC CLASS
Aromatase inhibitors (anti-estrogens).
The medicine is a hormonal treatment (also called “endocrine
therapy”) for breast cancer.
Development of breast cancer is often stimulated by estrogens,
which are female sex hormones. Letrozole Teva reduces the
amount of estrogen by blocking an enzyme (“aromatase”)
that is involved in estrogen production, and can therefore
block the growth of cancerous tissues in the breast that need
estrogen to grow. As a result, the cancer cells slow or stop their
development and/or spreading to other parts of the body.
If you have any questions regarding how Letrozole Teva works
or why it has been prescribed for you, refer to your doctor.
2. BEFORE USING THE MEDICINE
You should carefully follow all of the doctor’s orders. They may
differ from the general info